Outlook Therapeutics (OTLK) Research & Development (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Research & Development of $4.5 million for Q1 2026, up 2.12% year-over-year from $4.4 million in Q1 2025, and up 23.83% quarter-over-quarter from $3.6 million in Q4 2025.
Outlook Therapeutics (OTLK) Research & Development (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Research & Development for 12 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 2.12% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $21.2 million (down 43.78% YoY), while the FY2025 annual figure was $27.2 million, down 34.92% from the prior year.
- Research & Development advanced to $4.5 million in Q1 2026 per OTLK's latest filing, from $3.6 million in the prior quarter.
- Across five years, Research & Development topped out at $13.5 million in Q1 2024 and bottomed at $544948.0 in Q1 2023.
- Historically, Research & Development has averaged $8.0 million across 5 years, with a median of $9.0 million in 2022.
- Annual changes were most pronounced in 2023 — Research & Development plunged 95.54% — and 2024, when it jumped 2378.94%.
- Outlook Therapeutics' Research & Development stood at $9.9 million in 2022, then sank by 54.07% to $4.5 million in 2023, then soared by 113.28% to $9.7 million in 2024, then tumbled by 62.38% to $3.6 million in 2025, then rose by 23.83% to $4.5 million in 2026.
- Business Quant data shows OTLK's Research & Development at $4.5 million in Q1 2026, $3.6 million in Q4 2025, and $6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Outlook Therapeutics | 93.64 Mn | 82.40 Mn | -8,265.00 | 3.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | 3.63 Mn |
| Sep 30, 2025 | 5.98 Mn |
| Jun 30, 2025 | 7.13 Mn |
| Mar 31, 2025 | 4.41 Mn |
| Dec 31, 2024 | 9.66 Mn |
| Sep 30, 2024 | 12.52 Mn |
| Jun 30, 2024 | 11.20 Mn |
| Mar 31, 2024 | 13.51 Mn |
| Dec 31, 2023 | 4.53 Mn |
| Sep 30, 2023 | 4.94 Mn |
| Jun 30, 2023 | 11.10 Mn |
| Mar 31, 2023 | 544,948.00 |
| Dec 31, 2022 | 9.86 Mn |
| Sep 30, 2022 | 8.99 Mn |
| Jun 30, 2022 | 11.25 Mn |
| Mar 31, 2022 | 12.22 Mn |
| Dec 31, 2021 | 9.87 Mn |
| Sep 30, 2021 | 9.93 Mn |
| Jun 30, 2021 | 8.55 Mn |